CRDFCardiff Oncology, Inc.

$133M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$138,000+23.4% YoY

Gross Profit

-$3M-1951.0% margin

Operating Income

-$4M-3058.0% margin

Net Income

-$4M-2989.1% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

-14.8%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$149,000

Balance Sheet

Total Assets

$14M

Total Liabilities

$5M

Stockholders' Equity

$9M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$138,000	$111,813	+23.4%
Gross Profit	-$3M	-$92,623	-2806.8%
Operating Income	-$4M	-$4M	+4.9%
Net Income	-$4M	-$4M	-10.1%

Revenue Segments

Service

$101,43373%

Royalty

$36,85227%

CRDF Q2 2019 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena